Bladder Carcinoma

Overview

Bladder carcinoma is a malignancy arising in the urinary bladder. Urothelial carcinoma (formerly transitional cell carcinoma) is the predominant type; squamous cell carcinoma and adenocarcinoma are less common. Disease may remain confined to the urothelium or lamina propria, invade the detrusor muscle, or spread beyond the bladder. Painless visible haematuria is the classic presentation, although symptoms may be absent or haematuria may be microscopic. Bladder cancer is more common in older adults and men. Its stage and grade determine treatment and the risk of recurrence, progression and death.

⛶Expand image

Article figure

← → − + Fit 1:1 Info ×

Figure 1 of 1 — 100%

Anatomy & Physiology

The bladder is a distensible pelvic organ lined by urothelium. From the lumen outwards, the principal layers are urothelium, lamina propria, detrusor muscle and perivesical tissue. This anatomy underpins staging: invasion of the lamina propria is T1; invasion of detrusor muscle is T2. The trigone contains the ureteric openings and bladder outlet. Obstruction at a ureteric orifice can cause hydronephrosis. The bladder drains to pelvic lymph nodes, including obturator and internal and external iliac chains.

Aetiology & Risk Factors

Factor	Clinical relevance
Cigarette smoking	Major modifiable risk factor; risk increases with cumulative exposure.
Occupational exposure	Aromatic amines in some dye, rubber and chemical industries are associated with urothelial cancer.
Age and sex	Incidence increases with age and is higher in men.
Prior treatment	Cyclophosphamide exposure and pelvic radiotherapy increase risk.
Chronic inflammation	Long-standing irritation and Schistosoma haematobium infection are associated particularly with squamous cell carcinoma.
Other exposures	Aristolochic acid exposure is associated with urothelial malignancy.

Pathophysiology

Carcinogens excreted in urine contact the urothelium and can cause accumulated genetic damage. Many urothelial tumours grow as papillary lesions into the bladder lumen; others are flat high-grade lesions (CIS). Tumours may recur elsewhere in the urothelial lining. Progression through the basement membrane into lamina propria, then detrusor muscle and perivesical tissue, increases the risk of regional and distant spread.

Gross and Microscopic Pathology

Histology	Typical features
Urothelial carcinoma	Papillary or flat growth; graded low or high based on cytological and architectural atypia. Invasion and depth must be reported separately from grade.
Squamous cell carcinoma	Squamous differentiation, often associated with chronic irritation or schistosomiasis.
Adenocarcinoma	Gland-forming tumour; uncommon and requires distinction from secondary involvement.

Clinical Manifestation

• Haematuria: visible or microscopic, sometimes intermittent.
• Storage symptoms: frequency, urgency or dysuria, particularly with CIS; infection may coexist.
• Clots or outlet involvement: clot retention, difficulty voiding or incomplete emptying.
• Locally advanced disease: pelvic pain, hydronephrosis or flank pain from ureteric obstruction, and occasionally a palpable mass.
• Metastatic disease: weight loss, fatigue, bone pain or symptoms related to involved organs.

Examination may be normal in early disease. Assess general condition, abdominal or pelvic mass, signs of urinary retention and features of advanced malignancy when clinically indicated.

Diagnosis

Evaluate haematuria with a history (including smoking, infection and anticoagulant use), examination, urinalysis and urine culture when infection is suspected. Anticoagulant use does not by itself exclude malignancy. The extent of cystoscopy and upper tract imaging for microscopic haematuria should be guided by risk assessment; visible haematuria generally warrants prompt urological assessment.

Investigation	Purpose and key finding
Cystoscopy	Directly visualises bladder mucosa and identifies suspicious papillary or flat lesions.
TURBT with histopathology	Confirms histology, grade and depth of invasion; pathology should identify whether detrusor muscle is present in the specimen when needed for staging.
Urine cytology	Can support detection of high-grade urothelial cancer or CIS; a negative result does not exclude cancer, especially low-grade disease.
Upper tract imaging (usually CT urography when appropriate)	Assesses upper urinary tract urothelium, obstruction and alternative causes of haematuria.
Cross-sectional staging imaging	CT chest/abdomen/pelvis for suspected muscle-invasive or advanced disease; MRI may help assess local extent in selected cases.

Differential Diagnosis

• Urinary tract infection or prostatitis.
• Urinary stones.
• Renal or upper tract urothelial malignancy.
• Benign prostatic enlargement or other outlet pathology.
• Glomerular disease (especially with proteinuria, casts or impaired renal function).

Classification & Staging

Category	Definition	Implication
Ta	Non-invasive papillary urothelial carcinoma.	NMIBC; recurrence and progression risk depend on grade and other factors.
Tis (CIS)	Flat high-grade lesion confined to urothelium.	NMIBC but high-risk biology.
T1	Invades lamina propria but not detrusor muscle.	NMIBC; repeat resection is often needed to confirm stage and complete removal.
T2	Invades detrusor muscle.	MIBC; requires staging and discussion of definitive local and systemic treatment.
T3–T4	Invades perivesical tissue or adjacent organs.	Locally advanced disease; assess nodes and distant metastases.

Pathology also records histological variant, tumour grade, lymphovascular invasion and the presence of detrusor muscle. TNM N and M categories describe regional lymph nodes and distant metastases. NMIBC risk groups additionally use factors such as size, multiplicity, recurrence, grade, T stage and CIS; these guide intravesical therapy and surveillance.

Treatment

Management is chosen in a multidisciplinary setting according to stage, grade, NMIBC risk category, renal function, performance status, treatment eligibility and patient preferences.

Disease group	Typical approach
Low-risk NMIBC	Complete TURBT; a single immediate postoperative intravesical chemotherapy instillation may be offered when safe, followed by risk-adapted cystoscopic surveillance.
Intermediate-risk NMIBC	TURBT followed by risk-adapted intravesical chemotherapy or BCG and surveillance.
High-risk NMIBC / CIS	Adequate resection (repeat TURBT when indicated), intravesical BCG with maintenance when appropriate; discuss early radical cystectomy for very-high-risk or BCG-unresponsive disease.
Localised MIBC	Cisplatin-based neoadjuvant systemic treatment for eligible patients, followed by radical cystectomy and pelvic lymph-node dissection; selected patients may receive bladder-preserving trimodality treatment (maximal TURBT plus chemoradiotherapy).
Unresectable or metastatic urothelial cancer	Systemic therapy selected by current evidence, eligibility and availability, with symptom-directed supportive and palliative care.

Complications & Prognosis

Complications

• Recurrent bladder tumour or progression to muscle-invasive disease.
• Ureteric obstruction with hydronephrosis and renal impairment.
• Haematuria causing anaemia or clot retention.
• Regional or distant metastases, including to lymph nodes, bone, lung and liver.
• Treatment effects: BCG-related urinary symptoms or infection; after cystectomy, urinary diversion complications, infection, renal deterioration and sexual dysfunction.

Prognosis

Outcome depends chiefly on stage, grade and risk features. Low-risk NMIBC is often controlled with local treatment but may recur; high-risk NMIBC has a greater risk of progression and needs close surveillance. Muscle-invasive and metastatic disease carry substantially higher morbidity and mortality. Avoid applying a single survival percentage to all patients, as outcomes vary by stage, response to treatment and patient factors.

References

1. Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80(7):717-723.
2. Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA. 2020;324(19):1980-1991. doi:10.1001/jama.2020.17598.
3. Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016;70(3):458-466. doi:10.1016/j.eururo.2015.06.042.
4. Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ): a summary of the 2024 guidelines update. Eur Urol. 2024;86(6):531-549. doi:10.1016/j.eururo.2024.07.027.
5. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82-104. doi:10.1016/j.eururo.2020.03.055.
6. Barocas DA, Boorjian SA, Alvarez RD, Downs TM, Gross CP, Hamilton BD, et al. Microhematuria: AUA/SUFU guideline. J Urol. 2020;204(4):778-786. doi:10.1097/JU.0000000000001297.